Global trends in Candidemia: Review of reports from 1995-2005

Current Infectious Disease Reports

Volumn 7, Issue 6, 2005, Pages 429-439

  Morgan, Juliette ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

BLOODSTREAM INFECTION; BONE MARROW TRANSPLANTATION; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CATHETER INFECTION; DATA ANALYSIS; HEALTH SURVEY; HIGH RISK POPULATION; HOSPITAL INFECTION; HUMAN; INCIDENCE; INFECTION CONTROL; INTENSIVE CARE UNIT; MORTALITY; POPULATION RESEARCH; REVIEW; SPECIES DISTRIBUTION;

EID: 27944494024     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-005-0044-7     Document Type: Review

References (55)

1. Pfaller MA, Jones RN, Messer SA, et al.: National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998, 31:327-332.
2. Jarvis WR: Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995, 20:1526-1530.
3. Banerjee SN, Emori TG, Culver DH, et al.: Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med 1991, 91:86S-89S.
4. Beck-Sague CM, Jarvis WR: Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993, 167:1247-1251.
5. Fisher-Hoch SP, Hutwagner L: Opportunistic candidiasis: an epidemic of the 1980s. Clin Infect Dis 1995, 21:897-904.
6. Pittet D, Wenzel RP: Nosocomial bloodstream infections. Secular trends in rate, mortality, and contribution to total hospital deaths. Arch Intern Med 1995, 155:1177-1184.
7. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, et al.: Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002, 35:627-630.
8. Marr KA, Seidel K, Slavin MA, et al.: Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood 2000, 96:2055-2061.
9. Hobson RP: The global epidemiology of invasive Candida infections - is the tide turning? J Hosp Infect 2003, 55:159-168.
10. Karlowsky JA, Zhanel GG, Klym KA, et al.: Candidemia in a Canadian tertiary care hospital from 1976 to 1996. Diagn Microbiol Infect Dis 1997, 29:5-9.
11. Luzzati R, Amalfitano G, Lazzarini L, et al.: Nosocomial candidemia in non-neutropenic patients at an Italian tertiary care hospital. Eur J Clin Microbiol Infect Dis 2000, 19:602-607.
12. Vuides A, Peman J, Canton E, et al.: Candidemia at a tertiary-care hospital: epidemiology, treatment, clinical outcome and risk factors for death. Eur J Clin Microbiol Infect Dis 2002, 21:767-774.
13. Malani PN, Bradley SF, Little RS, Kauffman CA: Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 2001, 44:446-449.
14. Garbino J, Kolarova L, Rohner P, et al.: Secular trends of candidemia over 12 years in adult patients at a tertiary care hospital. Medicine 2002, 81:425-433.
15. Alonso-Valle H, Acha O, Garcia-Palomo JD, et al.: Candidemia in a tertiary care hospital: Epidemiology and factors influencing mortality. Eur J Clin Microbiol Infct Dis 2003, 22:254-257.
16. Hsueh PR, Teng LJ, Yang PC, et al.: Emergence of nosocomial candidemia at a teaching hospital in Taiwan from 1981 to 2000: increased susceptibility of Candida species to fluconazole. Microb Drug Resist 2002, 8:311-319.
17. Chen YC, Chang SC, Luh KT, Hsieh WC: Stable susceptibility of Candida blood isolates to fluconazole despite increasing use during the past 10 years. J Antimicrob Chemother 2003, 52:71-77.
18. McMullan R, McClurg R, Xu J, et al.: Trends in the epidemiology of Candida bloodstream infections in Northern Ireland between January 1984 and December 2000. J Infect 2002, 45:25-28.
19. San Miguel LG, Cobo J, Otheo E, et al.: Secular trends of candidemia in a large tertiary-care hospital from 1988 to 2000: emergence of Candida parapsilosis. Infect Control Hosp Epidemiol 2005, 26:548-552.
20. Doczi I, Dosa E, Hajdu E, Nagy E: Aetiology and antifungal susceptibility of yeast bloodstream infections in a Hungarian university hospital between 1996 and 2000. J Med Microbiol 2002, 51:677-681.
21. Schelenz S, Gransden WR: Candidaemia in a London teaching hospital: analysis of 128 cases over a 7-year period. Mycoses 2003, 46:390-396.
22. Ellis M, Hedstrom U, Jumaa P, Bener A: Epidemiology, presentation, management and outcome of candidemia in a tertiary care teaching hospital in the United Arab Emirates, 1995-2001. Med Mycol 2003, 41:521-528.
23. Duran MT, Velasco D, Canle D, et al.: Antifungal susceptibility of Candida species isolates from blood cultures in a five-year period (1997-2001). Enferm Infecc Microbiol Clin 2003, 21:488-492.
24. Boo TW, O'Reilly B, O'Leary J, Cryan B: Candidaemia in an Irish tertiary referral hospital: epidemiology and prognostic factors. Mycoses 2005, 48:251-259.
25. Richet H, Roux P, Des Champs C, et al.: Candidemia in French hospitals: incidence rates and characteristics. Clin Microbiol Infect 2002, 8:405-412.
26. Sandven P, Bevanger L, Digranes A, et al.: Constant low rate of fungemia in Norway, 1991 to 1996. The Norwegian Yeast Study Group. J Clin Microbiol 1998, 36:3455-3459.
27. Macphail GL, Taylor GD, Buchanan-Chell M, et al.: Epidemiology, treatment and outcome of candidemia: a five-year review at three Canadian hospitals. Mycoses 2002, 45:141-145.
28. Pappas PG, Rex JH, Lee J, et al.: A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003, 37:634-643.
29. Krcmery V Jr, Kovacicova G: Longitudinal 10-year prospective survey of fungaemia in Slovak Republic: trends in etiology in 310 episodes. Slovak Fungaemia study group. Diagn Microbiol Infect Dis 2000, 36:7-11.
30. Slavin MA; The epidemiology of candidaemia and mould infections in Australia. J Antimicrob Chemother 2002, 49(Suppl 1):3-6.
31. St-Germain G, Laverdiere M, Pelletier R, et al.: Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J Clin Microbiol 2001, 39:949-953.
32. Asmundsdottir LR, Erlendsdottir H, Gottfredsson M: Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol 2002, 40:3489-3492.
33. Poikonen E, Lyytikainen O, Anttila VJ, Ruutu P: Candidemia in Finland, 1995-1999. Emerg Infect Dis 2003, 9:985-990.
34. Tortorano AM, Biraghi E, Astolfi A, et al.: European Confederation of Medical Mycology (ECMM) prospective study of candidaemia: report from one Italian region. J Hosp Infect 2002, 51:297-304.
35. Kibbler CC, Seaton S, Barnes RA, et al.: Management and outcome of bloodstream infections due to Candida species in England and Wales. J Hosp Infect 2003, 54:18-24.
36. Tortorano AM, Peman J, Bernhardt H, et al.: ECMM Working Group on Candidaemia. Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 2004, 23:317-322.
37. Peman J, Canton E, Gobernado M, et al.: Epidemiology and antifungal susceptibility of Candida species isolated from blood: results of a 2-year multicentre study in Spain. Eur J Clin Microbiol Infect Dis 2005, 24:23-30.
38. Klingspor L, Tornqvist E, Johansson A, et al.: A prospective epidemiological survey of candidaemia in Sweden. Scand J Infect Dis 2004, 36:52-55.
39. Marchetti O, Bille J, Fluckiger U, Eggimann et al.: Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis 2004, 38:311-320.
40. Hajjeh RA, Sofair AN, Harrison LH, et al.: Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J Clin Microbiol 2004, 42:1519-1527.
41. Godoy P, Tiraboschi IN, Severo LC, et al.: Species distribution and antifungal susceptibility profile of Candida spp. bloodstream isolates from Latin American hospitals. Mem Inst Oswaldo Cruz 2003, 98:401-405.
42. Diekema DJ, Messer SA, Brueggemann AB, et al.: Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study. J Clin Microbiol 2002, 40:1298-1302.
43. Martin D, Persat F, Piens MA, Picot S: Candida species distribution in bloodstream cultures in Lyon, France, 1998-2001. Eur J Clin Microbiol Infect Dis 2005, 24:329-333.
44. Silva V, Diaz MC, Febre N, et al.: Invasive fungal infections in Chile: a multicenter study of fungal prevalence and susceptibility during a 1-year period. Med Mycol 2004, 42:333-339.
45. Swinne D, Watelle M, Suetens C, et al.: A one-year survey of candidemia in Belgium in 2002. Epidemiol Infect 2004, 132:1175-1180.
46. Takakura S, Fujihara N, Saito T, et al.: National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin. J Antimicrob Chemother 2004, 53:283-289.
47. Almirante B, Rodriguez D, Park BJ, et al.: Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 2005, 43:1829-1835.
48. Abi-Said D, Anaissie E, Uzun O, et al.: The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997, 24:1122-1128. [Published erratum appears in Clin Infect Dis 1997 25:352.]
49. Wingard JR, Merz WG, Rinaldi MG, et al.: Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991, 325:1274-1277.
50. Girmenia C, Martino P: Fluconazole and the changing epidemiology of candidemia. Clin Infect Dis 1998, 27:232-233.
51. Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B: Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003, 20:153-163.
52. Roilides E, Farmaki E, Evdoridou J, Dotis, et al.: Neonatal candidiasis: analysis of epidemiology, drug susceptibility, and molecular typing of causative isolates. Eur J Clin Microbiol Infect Dis 2004, 23:745-750.
53. Tortorano AM, Caspani L, Rigoni AL, et al.: Candidosis in the intensive care unit: a 20-year survey. J Hosp Infect 2004, 57:8-13.
54. Richards C, Emori TG, Edwards J, et al.: Characteristics of hospitals and infection control professionals participating in the National Nosocomial Infections Surveillance System 1999. Am J Infect Control 2001, 29:400-403.
55. Morgan J, Meltzer MI, Plikaytis BD, et al.: Excess mortality, hospital stay, and cost due to candidemia: a case-control study using data from population-based candidemia surveillance. Infect Control Hosp Epidemiol 2005, 26:540-547.